Varenicline Effects In Schizophrenic Smokers
| Status: | Completed |
|---|---|
| Conditions: | Schizophrenia, Smoking Cessation, Tobacco Consumers |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 9/22/2018 |
| Start Date: | June 2007 |
| End Date: | December 2010 |
Evaluation of Varenicline's Clinical Efficacy for Continued Smoking Abstinence When Used in the Clinical Treatment of Schizophrenic Patients Hospitalized in an Institution With a Ban on Cigarette Smoking
This is an open label pre-post study of the effects of clinical treatment with varenicline on
1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in
schizophrenic patients, and 3) psychopathology in schizophrenic patients. Patients are
assessed on subjective and objective measures of smoking, selected cognitive measures, and
special chemical measures, during baseline testing and during 8 weeks of treatment with
varenicline (1-2 mg/day).
1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in
schizophrenic patients, and 3) psychopathology in schizophrenic patients. Patients are
assessed on subjective and objective measures of smoking, selected cognitive measures, and
special chemical measures, during baseline testing and during 8 weeks of treatment with
varenicline (1-2 mg/day).
Inclusion Criteria:
- Clinical Diagnosis of Schizophrenia or Schizoaffective Psychosis
- Recent History of Cigarette smoking
- Ages 18-65
We found this trial at
1
site
Click here to add this to my saved trials
